Device Trial Radar · NCT04504188
Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator
Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 8, 2021
Primary completion
Sep 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Zoll Medical CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 7, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \< 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB/ivabradine dosage, as compared to a prior historical control.
Conditions
- Cardiomyopathies
- Heart Failure
Interventions
Heart Rate Monitor Enhanced Treatment OptimizationDevice
Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Heart Rate ControlTime frame: 90 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
TriHealth Hatton Research Institute
Cincinnati, Ohio · Recruiting
Texas Cardiology Associates of Houston
Kingwood, Texas · Terminated
CardioVoyage
McKinney, Texas · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.